Dr. (Prof) Deepak Natarajan, a distinguished medical expert, brought to light pivotal findings from a recent study published in February 2024 in the highly respected journal Vaccine. The research, a massive multi-country analysis of vaccinated individuals, identified significantly increased risks for specific adverse events of special interest (AESI) following vaccination with the AstraZeneca COVID-19 vaccine.
The comprehensive study meticulously examined 13 potential adverse events associated with COVID-19 vaccination. Dr. Natarajan’s commentary focused on three particularly severe conditions that showed notable increases with the AstraZeneca adenovirus vector vaccine: Guillain-Barré Syndrome (GBS), Cerebral Venous Sinus Thrombosis (CVST), and Myocarditis/Pericarditis.
Researchers utilized an Observed-to-Expected (OE) ratio methodology, comparing the incidence of these diseases after vaccination against their background prevalence prior to the pandemic. The study period varied by region, ranging from February to December 2021 in Australia to December 2020 to August 2023 in Argentina, with adverse events observed only up to 42 days post-vaccination.
Significant Observations Pointed Out by Dr. Natarajan
- Guillain-Barré Syndrome (GBS): This severe neurological disorder, characterized by profound weakness, numbness, pain, and potential respiratory failure requiring ventilator support, showed an OE ratio of 2.59 with the AstraZeneca vaccine. This indicates the observed incidence was 259% higher than expected based on pre-pandemic rates. Dr. Natarajan emphasized, “GBS is not an innocuous condition; it demands attention and treatment, and its elevated incidence is a very serious concern.”
- Cerebral Venous Sinus Thrombosis (CVST): A lethal blood clot in the brain, CVST can present with severe headaches, visual disturbances, paralysis, epileptic fits, and carries a high mortality rate ranging from 25% to 80%. The study reported an OE ratio of 3.23 for CVST with the AstraZeneca vaccine, signifying a 323% increase in observed rates compared to background. “This is a life-threatening condition, and the observed increase is alarmingly high,” stated Dr. Natarajan.
- Myocarditis and Pericarditis: These inflammatory conditions of the heart muscle (myocarditis) and the heart’s outer lining (pericarditis) are recognized as serious. While myocarditis saw an approximate 30-35% increase with the AstraZeneca vaccine, pericarditis exhibited a particularly striking OE ratio of 6.9 after the third dose of the AstraZeneca vaccine. This translates to a 690% greater observed rate than expected. Dr. Natarajan strongly cautioned against downplaying these conditions, stating, “Any assertion that myocarditis or pericarditis are universally mild or temporary is a grave misrepresentation. These are serious, potentially deadly problems with significant long-term implications.”
Dr. Natarajan stressed the critical importance of these findings for public health and individual risk assessment. “The rigorous data from this study, published in one of the most respected journals in vaccinology, provides undeniable evidence of significantly increased risks for severe adverse events associated with the AstraZeneca vaccine,” he added. “It underscores the necessity for transparent communication regarding vaccine risks and benefits, particularly when considering vaccination for individuals who may have a very low risk from the virus itself.”
The study’s meticulous methodology, including the use of OE ratios against robust background data, provides a clear basis for understanding the elevated risks identified.
About Dr. (Prof) Deepak Natarajan:
DIRECTOR INTERVENTIONAL CARDIOLOGY
MBBS,MD,DM
DELHI, NCR
Also Read: